Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

Harlan Krumholz, MD, SM, editor-in-chief of the Journal of the American College of Cardiology (JACC), and a cardiologist and the Harold H. Hines, Jr. Professor of Medicine at the Yale school Medicine, explains some of the key technology advances he is watching across cardiology.

JACC editor excited by progress during a 'very important moment' for cardiology

Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology, explains some of the key technology and treatment trends he has his eyes on.

IVUS Intravascular Ultrasound ACC

Intravascular imaging during PCI: Should cardiologists choose IVUS or OCT?

Which modality should care teams choose for PCI guidance? While there's an argument to be made for choosing IVUS over OCT, some specialists think the two treatment options are close to equal in terms of patient outcomes. 

Shockwave Medical, a Johnson & Johnson MedTech company, has officially launched its Shockwave E8 Peripheral IVL Catheter in the United States. Shockwave’s E8 catheter was designed specifically to treat patients with calcified femoropopliteal and below-the-knee (BTK) peripheral artery disease (PAD), including those diagnosed with complex chronic limb-threatening ischemia (CLTI).

Shockwave Medical launches new FDA-approved IVL catheter for PAD, CLTI

The new device, already cleared by the FDA, was designed to treat femoropopliteal and below-the-knee PAD. 

Biotronik has received U.S. Food and Drug Administration (FDA) approval to make its Solia S lead and Selectra 3D catheter available for a new indication: left bundle branch area pacing (LBBAP).

FDA approves Biotronik lead, catheter for left bundle branch area pacing

LBBAP is a relatively new alternative to biventricular pacing. The FDA's decision was based largely on data from the BIO-CONDUCT clinical trial.

SpectraWAVE, a Massachusetts-based imaging company focused on treatments for patients with coronary artery disease (CAD), has closed a $50 million funding round. Johnson & Johnson Innovation led the round, and other participants included S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, NovaVenture and Heartwork Capital.

SpectraWAVE raises $50M for FDA-cleared intravascular imaging technology

The funds, including a significant investment from Johnson & Johnson, are expected to go toward expanding access to the company's HyperVue Imaging System and exploring new features.

A demonstration of SenitAR's augmented reality (AR) technology for electrophysiology lab procedures during the Heart Rhythm Society 2024 meeting. This is one of at least six FDA-cleared clinical AR and virtual reality applications that aimed at enhancing cardiology workflow and patient outcomes. Photo by Dave Fornell

A glimpse into the future: FDA has cleared multiple AR, VR tools for cardiology

Heart teams already have access to several augmented reality and virtual reality offerings, and many more are on the way.

A heart team at King Faisal Specialist Hospital & Research Center (KFSHRC) in Riyadh, Saudi Arabia, made a bit of history, completing the world’s first fully robotic heart transplant. The procedure, which lasted roughly two and half hours, was performed on a 16-year-old patient with end-stage heart failure. One reason this patient was selected was the fact that he had specifically requested the heart team not open his chest.

Surgeons make history, perform world’s first fully robotic heart transplant

The procedure, which lasted roughly two and half hours, was performed on a 16-year-old patient with end-stage heart failure. 

Nemours Children's Hospital pediatric cardiologists explain lessons learned about cardiac involvement and long-term issues from multisystem inflammatory syndrome in children (MIS-C), a rare but serious disease caused by exposure to the COVID-19 virus. #MIS-C #COVID #coronavirus #SARSCoV2

A key update on how COVID-19 caused dangerous MIS-C inflammation in children

The rise of MIS-C during the COVID-19 pandemic alarmed physicians and patients alike, and the exact cause was unclear. Now, new NIH-funded research appears to provide some answers.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup